Pfizer and BioNTech to Supply 100 Million Additional Doses of COVID-19 Vaccine to United States

February 15, 2021
Pharmaceutical Technology Editors

The US government will pay $1.95 billion for the additional 100 million doses, bringing the total number of doses supplied by the companies up to 300 million.

Pfizer and BioNTech announced on Feb. 12, 2021 that it will supply the United States with an additional 100 million doses of its Pfizer-BioNTech COVID-19 vaccine, bringing the total number of doses supplied by the companies up to 300 million.

Under the terms of the agreement, the US government will pay $1.95 billion for the additional 100 million doses, Pfizer said in a company press release. The vaccine is currently being manufactured at Pfizer’s facility in Kalamazoo, MI, and holds emergency use authorizations or equivalent in the US, United Kingdom, and Canada.

“We support the new administration's plan to vaccinate as many people as quickly as possible because there is an urgent need to help protect people from this virus, here in the US and across the globe,” said Albert Bourla, chairman and CEO, Pfizer, in the press release. "We are pleased to work with the administration to provide these additional vaccines, so that more Americans receive their first and second doses as soon as possible."

“It is our objective to supply as many doses of our COVID-19 vaccine as possible to people in order to help end this pandemic, reduce the hospitalization of especially elderly people, and bring us back to our normal lives,” added Ugur Sahin, MD, CEO and co-founder of BioNTech, in the press release.

Source: Pfizer